SVB FINANCIAL GROUP
Q1 2023 Form 13-F

MENLO PARK, CALIFORNIA
CIK 0000719739 · Publicly traded company
$52.3M Reported Value Total
Reported value
$52.3M
Quarter over quarter
+42.2%
Holdings
28
Top-10 concentration
94.4%

Filing Structure

Reports holdings for

  • SVB Capital Management LLC · File #028-23867 · Q1 2024 – Q2 2024 · declared by one filing
  • SVB Capital Management, LLC (not a 13F filer in our records) · Q4 2023 – Q4 2023 · declared by one filing

Key People

Directors & officers from Form 4 filings
Beck Daniel J
Chief Financial Officer
Becker Gregory W
President and CEO
Olson Kim Petra
Chief Risk Officer
Draper Michelle
Chief Marketing Officer
Cox Philip C
Chief Operations Officer
Descheneaux Michael
President, Silicon Valley Bank

Description and Activity

SVB Financial Group, incorporated in Delaware in March 1999, is a diversified financial services and bank holding company primarily operating through its subsidiary, Silicon Valley Bank. The company provides banking and financial products to clients in the U.S. and international innovation markets, focusing on technology, life sciences/healthcare, private equity/venture capital, and premium wine industries. As of December 31, 2022, SVB Financial reported total assets of $211.8 billion, total loans of $74.3 billion, and total deposits of $173.1 billion.

The company's operations are divided into four segments: Silicon Valley Bank, SVB Private, SVB Capital, and SVB Securities. Silicon Valley Bank offers commercial banking services, including credit solutions, treasury management, foreign exchange, and trade finance products, particularly to clients in technology and healthcare sectors. SVB Private serves high-net-worth clients, mainly private equity and venture capital professionals, with private banking and wealth management services. SVB Capital manages funds for third-party investors, generating income through investment returns and management fees. SVB Securities functions as an investment bank, providing capital raising, M&A advisory, and equity research services, especially in healthcare and technology sectors.

SVB Financial generates revenue through net interest income (NII) and noninterest income. For the year ended December 31, 2022, NII was $4.5 billion, while noninterest income was $1.7 billion, primarily from fee-based services and investment banking activities. Most of its revenue comes from U.S. clients, with less than 10% from foreign clients. The client base includes emerging, mid-stage, and established companies in technology and life sciences, as well as private equity and venture capital firms, and premium wine producers in the western U.S. Key factors impacting the company's performance include competition from traditional banks, alternative lenders, Fintech companies, and investment banks.

Company description summarized from 10-K filing.

Filing Navigation

13F Metrics

Loading 13F Metrics

Q1 2023 13F record

Q1 2023 13F filing summary

Q1 2023 Form 13F portfolio summary
Period of report March 31, 2023
Filed May 15, 2023
Form 13F-HR
Reported value $52.3M
Positions 28
Change in reported value +42.9%
New positions 4
Exited positions 6
Position turnover 29.4%
Top-10 concentration 94.4%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2024 13F
Filed Nov 12, 2024
1 $434.2K
Q2 2024 13F
Filed Aug 14, 2024
11 $142.4M
Q1 2024 13F
Filed May 14, 2024
13 $181.4M
Q4 2023 13F
Filed Feb 14, 2024
13 $112.8M
Q3 2023 13F
Filed Nov 14, 2023
21 $53.2M
Q2 2023 13F
Filed Aug 11, 2023
24 $52.9M
Q1 2023 13F
Filed May 15, 2023
28 $52.3M
Q4 2022 13F
Filed Feb 14, 2023
30 $36.6M

Top 20 holdings · Q1 2023

Largest Q1 2023 13F positions by reported value
# Holding Reported value % of portfolio
1 COIN COINBASE GLOBAL INC $27.5M 52.61%
2 OKTA OKTA INC $8.6M 16.48%
3 ROOT ROOT INC $3.5M 6.76%
4 OBIO ORCHESTRA BIOMED HOLDINGS INC $2.5M 4.76%
5 AXSM AXSOME THERAPEUTICS INC $2.1M 3.99%
6 FROG JFROG LTD $1.9M 3.59%
7 GPCR STRUCTURE THERAPEUTICS INC $841.0K 1.61%
8 DICE DICE THERAPEUTICS INC $832.7K 1.59%
9 CMAX CAREMAX INC $801.0K 1.53%
10 PATH UIPATH INC $790.7K 1.51%
11 PL PLANET LABS PBC $676.3K 1.29%
12 ROVR ROVER GROUP INC $478.1K 0.91%
13 MLTX MOONLAKE IMMUNOTHERAPEUTICS $345.9K 0.66%
14 CGEM CULLINAN ONCOLOGY INC $207.4K 0.4%
15 GBIO GENERATION BIO CO $173.7K 0.33%
16 SKLZXXXX SKILLZ INC $162.5K 0.31%
17 CRBU CARIBOU BIOSCIENCES INC $146.7K 0.28%
18 ALVR ALLOVIR INC $135.6K 0.26%
19 PACB PACIFIC BIOSCIENCES CALIF IN $118.7K 0.23%
20 KNTE KINNATE BIOPHARMA INC $97.4K 0.19%

Values as reported on the Q1 2023 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings